Faculty Summaries
Brian L. Egleston
Brian L Egleston, PhD
Associate Research Professor
Office Phone: 215-214-3917
Fax: 215-728-2553
Office: R383

Selected First/Last Author Publications

  • Austin, S.R., Wong, Y.N., Uzzo, R.G., Beck, J.R., Egleston, B.L. Why summary measures such as the Charlson Comorbidity Index and Elixhauser Score work. Medical Care 2013; in press.
  • Egleston BL. Comment on Imai K, Tingley D, Yamamoto T. Experimental designs for identifying causal mechanisms. J. R. Statist. Soc. A 2013; 176(1):35-36.
  • Bleicher RJ, Ruth K, Sigurdson ER, Ross E, Wong YN, Patel SA, Boraas M, Topham NS, Egleston BL. Preoperative Delays in the US Medicare Population With Breast Cancer. J Clin Oncol. 2012; 30(36):4485-92.
  • Egleston BL, Miller SM, Meropol NJ. The impact of misclassification due to survey response fatigue on estimation and identifiability of treatment effects. Statistics in Medicine. 2011;30(30):3560-72.
  • Egleston BL. Response to Pearl’s Comments on Principal Stratification. The International Journal of Biostatistics. 2011;7(1) Article 24.
  • Egleston BL, Cropsey KL, Lazev AB, Heckman CJ. Tutorial on principal stratification-based sensitivity analysis: Application to smoking cessation studies. Clinical Trials. 2010;7(3):286-98. PMCID: PMC2874094
  • Egleston BL, Chandler DW, Dorgan JF. Validity of estimating non-SHBG bound testosterone and estradiol from total hormone measurements in boys and girls. Annals of Clinical Biochemistry. 2010;47(Pt 3):233-24.
  • Egleston BL, Dunbrack RL Jr, Hall MJ. Clinical trials that explicitly exclude gay and lesbian patients. New England Journal of Medicine. 2010;362(11):1054-1055.
  • Egleston BL, Meireles SI, Flieder DB, Clapper ML. Population-based trends in lung cancer incidence in women. Semin Oncol. 2009;36(6):506-515.
  • Egleston BL, Scharfstein DO, MacKenzie E. On estimation of the survivor average causal effect in observational studies when important confounders are missing due to death. Biometrics. 2009;65(2):497-504.
  • Egleston BL, Wong YN. Sensitivity analysis to investigate the impact of a missing covariate on survival analyses using cancer registry data. Stat Med. 2009;28(10):1498-1511.
  • Egleston BL, Scharfstein DO, Freeman EE, West SK. Causal inference for non-mortality outcomes in the presence of death. Biostatistics. 2007;8(3):526-545.
  • Egleston BL, Rudberg MA, Brody JA. State variation in nursing home mortality outcomes according to do-not-resuscitate status. J Gerontol A Biol Sci Med Sci. 2000;55:M215-220.
  • Egleston BL, Rudberg MA, Brody JA. Prior living arrangements and nursing home resident admission ADL characteristics: A study of two states. J Gerontol B Psychol Sci Soc Sci. 1999;54:S202-S206.

Selected Collaborative Publications

  • Ahmed AA, Egleston B, Alcantara P, Li L, Pollack A, Horwitz EM, Buyyounouski MK. A Novel Method for Predicting Late Genitourinary Toxicity After Prostate Radiation Therapy and the Need for Age-Based Risk-Adapted Dose Constraints. Int J Radiat Oncol Biol Phys. 2013 86(4):709-15.
  • Seeger-Nukpezah T, Proia DA, Egleston BL, Nikonova AS, Cai KQ, Hensley HH, Serebriiskii IG, Golemis EA. Inhibiting the HSP90 chaperone slows cyst growth in a mouse model of autosomal dominant polycystic kidney disease (ADPKD). Proc Natl Acad Sci USA 2013; 110(31):12786-91.
  • Wong YN, Egleston BL, Sachdeva K, Eghan N, Pirollo M, Stump TK, Beck JR, Armstrong K, Schwartz JS, Meropol NJ. Cancer Patients' Trade-offs Among Efficacy, Toxicity, and Out-of-Pocket Cost in the Curative and Noncurative Setting. Medical Care 2013; 51(9):838-845.
  • Van Cleave JH., Egleston, B.L., Ercolano, E., McCorkle, R. Symptom Distress in Older Adults Following Cancer Surgery. Cancer Nurs 2013; 36(4):292-300, 2013.
  • Corcoran AT, Smaldone MC, Egleston BL, Simhan J, Ginzburg S, Morgan TM, Walton J, Chen DY, Viterbo R, Greenberg RE, Uzzo RG, Kutikov A. Comparison of prostate cancer diagnosis in patients receiving unrelated urological and non-urological cancer care. BJU Int. 2013; 112(2):161-8.
  • Moy B, Bradbury AR, Helft PR, Egleston BL, Sheikh-Salah M, Peppercorn J. Correlation between financial relationships with commercial interests and research prominence at an oncology meeting. J Clin Oncol 2013; 31(21):2678-84.
  • Fang CY, Egleston BL, Ridge JA, Lango MN, Bovbjerg DH, Studts JL, Burtness BA, Einarson MB, Klein-Szanto AJ. A pilot study of psychosocial functioning and vascular endothelial growth factor in head and neck cancer patients. Head Neck 2013; in press
  • Stump TK, Eghan N, Egleston BL, Hamilton O, Pirollo M, Schwartz JS, Armstrong K, Beck JR, Meropol NJ, Wong YN. Cost Concerns of Patients With Cancer. J Oncol Pract 2013; 9(5):251-7.
  • Dorgan JF, Klifa C, Deshmukh S, Egleston BL, Shepherd JA, Kwiterovich PO Jr., Van Horn L, Snetselaar LG, Stevens VJ, Robson AM, Lasser NL, Hylton NM. Menstrual and reproductive characteristics and breast density in young women. Cancer Causes Control 2013; in press.
  • Simhan J, Smaldone MC, Egleston BL, Canter D, Sterious SN, Corcoran AT, Ginzburg S, Uzzo RG, Kutikov A. Nephron Sparing Management versus Radical Nephroureterectomy for Low or Moderate Grade, Low Stage Upper Tract Urothelial Carcinoma. BJU Int. 2013, in press.
  • Patrick-Miller L, Egleston BL, Daly M, Stevens E, Fetzer D, Forman A, Bealin L, Rybak C, Peterson C, Corbman M, Bradbury AR. Implementation and outcomes of telephone disclosure of clinical BRCA1/2 test results. Patient Educ Couns 2013; in press.
  • Canter DJ, Mallin K, Uzzo RG, Egleston BL, Simhan J, Walton J, Smaldone MC, Master VA, Bratslavsky G, Kutikov A. Association of tumor size with metastatic potential and survival in patients with adrenocortical carcinoma: an analysis of the National Cancer Database. Can J Urol 2013 20(5):6915-6921.
  • Montgomery SV, Barsevick AM, Egleston BL, Bingler R, Ruth K, Miller SM, Malick J, Cescon TP, Daly MB. Preparing individuals to communicate genetic test results to their relatives: report of a randomized control trial. Fam Cancer 2013; in press
  • Jackson MD, Tulloch-Reid MK, McFarlane-Anderson N, Watson A, Seers V, Bennett FI, Egleston B, Ragin C. Complex interaction between serum folate levels and genetic polymorphisms in folate pathway genes: biomarkers of prostate cancer aggressiveness. Genes Nutr 2013; 8(2):199-207.
  • Giordano A, Egleston BL, Hajage D, Bland J, Hortobagyi GN, Reuben JM, Pierga JY, Cristofanilli M, Bidard FC. Establishment and validation of circulating tumor cell-based prognostic nomograms in first-line metastatic breast cancer patients. Clin Cancer Res 2013; 19(6):1596-602.
  • Sukhanova A, Gorin A, Serebriiskii IG, Gabitova L, Zheng H, Restifo D, Egleston BL, et al. Targeting C4-demethylating genes in the cholesterol pathway sensitizes cancer cells to EGFR inhibitors via increased EGFR degradation. Cancer Discov 2013; 3(1):96-111.
  • Little JL, Serzhanova V, Izumchenko E, Egleston BL, Parise E, Klein-Szanto AJ, Loudon G, Shubina M, Seo S, Kurokawa M, Ochs MF, Golemis EA. A requirement for Nedd9 in luminal progenitor cells prior to mammary tumorigenesis in MMTV-HER2/ErbB2 mice. Oncogene 2013, in press.
  • Stoyanova R, Pahlajani NH, Egleston BL, Buyyounouski MK, Chen DY, Horwitz EM, Pollack A. The impact of dose-escalated radiotherapy plus androgen deprivation for prostate cancer using 2 linked nomograms. Cancer 2013; 119(5):1080-8.
  • Meropol NJ, Egleston BL, Buzaglo JS, et al. A Web-based communication aid for patients with cancer: The CONNECT Study. Cancer 2013; 119(7):1437-45.
  • Bradbury AR, Patrick-Miller L, Egleston BL, Olopade OI, Daly MB, Moore CW, Sands CB, Schmidheiser H, Kondamudi PK, Feigon M, Ibe CN, Daugherty CK. When parents disclose BRCA1/2 test results: Their communication and perceptions of offspring response. Cancer 2012; 118(13):3417-25.
  • Crivello ML, Ruth K, Sigurdson ER, Egleston BL, Evers K, Wong YN, Boraas M, Bleicher RJ. Advanced Imaging Modalities in Early Stage Breast Cancer: Preoperative Use in the United States Medicare Population. Ann Surg Oncol. 2012; 78(3):244-245.
  • Doss M, Egleston BL, Litwin S. Comments on "Studies of the Mortality of Atomic Bomb Survivors, Report 14, 1950-2003: An Overview of Cancer and Noncancer Diseases" Radiat Res. 2012; 178(3):244-5.
  • Van Cleave JH, Egleston BL, Bourbonniere M, Cardone L, McCorkle R. Functional Status in Older Women Following Gynecological Cancer Surgery: Can Choice of Measure Influence Evidence for Clinical Practice? Geriatr Nurs. 2012, in press.
  • Fang CY, Egleston BL, Gabriel KP, Stevens VJ, Kwiterovich PO Jr., Snetselaar LG, Longacre ML, Dorgan JF. Depressive symptoms and serum lipid levels in young adult women. J Behav Med. 2012, in press.
  • Dorgan JF, Klifa C, Shepherd JA, Egleston BL, et al. Height, adiposity and body fat distribution and breast density in young women. Breast Cancer Res. 2012; 14(4):R107.
  • Lee CK, Marschner IC, Simes RJ, Voysey M, Egleston B, Hudes G, de Souza P. Increase in cholesterol predicts survival advantage in renal cell carcinoma patients treated with temsirolimus. Clin Cancer Res 2012: 18(11):3188-96.
  • Miller SM, Hudson SV, Egleston BL, Manne S, Buzaglo JS, Devarajan K, Fleisher L, Millard J, Solarino N, Trinastic J, Meropol NJ. The relationships among knowledge, self-efficacy, preparedness, decisional conflict, and decisions to participate in a cancer clinical trial. Psychooncology 2013; 22(3):481-489.
  • Canter D, Egleston B, WongYN, Smaldone MC, Simhan J, Greenberg RE, Uzzo RG, Kutikov A. Use of radical cystectomy as initial therapy for the treatment of high-grade T1 urothelial carcinoma of the bladder: A SEER database analysis. Urol Oncol 2013; 31(6):866-70.
  • Weiss CO, Wolff JL, Egleston B, Seplaki CL, Fried LP. Incident preclinical mobility disability (PCMD) increases future risk of new difficulty walking and reduction in walking activity. Arch Gerontol Geriatr. 2012; 54(3):e329-33.
  • Smaldone MC, Kutikov A, Egleston B, Simhan J, Canter DJ, Teper E, Viterbo R, Chen DY, Greenberg RE, Uzzo RG. Assessing Performance Trends in Laparoscopic Nephrectomy and Nephron-sparing Surgery for Localized Renal Tumors. Urology 2012; 80(2):286-92.
  • Kutikov A, Smaldone MC, Egleston BL, Uzzo RG. Should Partial Nephrectomy Be Offered to All Patients Whenever Technically Feasible? Eur Urol. 2012; 61(4):732-4.
  • Kutikov A, Rozenfeld B, Egleston BL, Sirohi M, Hwang RW, Uzzo RG. Academic Ranking Score: A Publication-Based Reproducible Metric of Thought Leadership in Urology. Eur Urol. 2012; 61(3):435-9.
  • Stitzenberg KB, Wong YN, Nielsen ME, Egleston BL, Uzzo RG. Trends in radical prostatectomy: centralization, robotics, and access to urologic cancer care. Cancer 2012; 118(1):54-62.
  • Smaldone MC, Kutikov A, Egleston BL, Canter DJ, Viterbo R, Chen DY, Jewett MA, Greenberg RE, Uzzo RG. Small renal masses progressing to metastases under active surveillance: A systematic review and pooled analysis. Cancer 2012; 118(4):997-1006.
  • Smaldone MC, Egleston B, Uzzo RG, Kutikov A. Does Partial Nephrectomy Result in a Durable Overall Survival Benefit in the Medicare Population? J Urol. 2012; 188(6):2089-2094.
  • Shaw CM, Stanczyk FZ, Egleston BL, Kahle LL, Spittle CS, Godwin AK, Brinton LA, Dorgan JF. Serum antimullerian hormone in healthy premenopausal women. Fertil Steril. 2011; 95(8):2718-21.
  • Canter D, Kutikov A, Manley B, Egleston B, Simhan J, Smaldone M, Teper E, Viterbo R, Chen DY, Greenberg RE, Uzzo RG. Utility of the R.E.N.A.L. nephrometry scoring system in objectifying treatment decision-making of the enhancing renal mass. Urology 2011; 78(5):1089-94.
  • Mustafa A, Gupta S, Hudes GR, Egleston BL, Uzzo RG, Kruger W.D. Serum amino acid levels as a biomarker for renal cell carcinoma. J Urol. 2011; 186(4):1206-12.
  • Kutikov A, Smaldone MC, Egleston BL, Manley BJ, Canter DJ, Simhan J, Boorjian SA, Viterbo R, Chen DY, Greenberg RE, Uzzo RG. Anatomic Features of Enhancing Renal Masses Predict Malignant and High-Grade Pathology: A Preoperative Nomogram Using the RENAL Nephrometry Score. Eur Urol 2011; 60(2):241-8.
  • Van Cleave JH, Egleston BL, McCorkle R. Factors affecting recovery of functional status in older adults after cancer surgery. J Am Geriatr Soc. 2011; 59(1):34-43.
  • Van Cleave JH, Egleston BL, Bourbonniere M, McCorkle R. Combining extant datasets with differing outcome measures across studies of older adults after cancer surgery. Res Gerontol Nurs 2011; 4(1):36-46.
  • Long CJ, Kutikov A, Canter DJ, Egleston BL, Chen DY, Viterbo R, Boorjian SA, Uzzo RG. Percutaneous vs surgical cryoablation of the small renal mass: is efficacy compromised? BJU Int. 2011; 107(9):1376-80.
  • Bradbury AR, Patrick-Miller L, Fetzer D, Egleston B, Cummings SA, Forman A, Bealin L, Peterson C, Corbman M, O'Connell J, Daly MB. Genetic counselor opinions of, and experiences with telephone communication of BRCA1/2 test results. Clin Genet. 201; 79(2):125-131.
  • Singh MK, Izumchenko E, Klein-Szanto AJ, Egleston BL, Wolfson M, Golemis EA. Enhanced genetic instability and dasatinib sensitivity in mammary tumor cells lacking NEDD9. Cancer Res. 2010; 7(21):8907-8916.
  • Heckman CJ, Egleston BL, Hofmann MT. Efficacy of motivational interviewing for smoking cessation: a systematic review and meta-analysis. Tob Control. 2010; 19(5):410-416.
  • Bradbury AR, Patrick-Miller L, Egleston B, Sands CB, Li T, Schmidheiser H, Feigon M, Ibe CN, Hlubocky FJ, Hope K, Jackson S, Corbman M, Olopade OI, Daly M, Daugherty CK. Parent opinions regarding the genetic testing of minors for BRCA1/2. J Clin Oncol 2010;28(21):3498-505.
  • Hall MJ, Egleston B, Miller SM, Buzaglo JS, Millard J, Ridgway C, Damjanov N, Sprandio JD, Meropol NJ. Barriers to participation in cancer prevention clinical trials. Acta Oncol 2010;49(6):757-66. PMCID: PMC2901417
  • Wong YN, Hamilton O, Egleston B, Salador K, Murphy C, Meropol NJ. Understanding How Out-of-Pocket Expenses, Treatment Value, and Patient Characteristics Influence Treatment Choices. Oncologist 2010;15(6):566-76. PMCID: PMC2892556
  • Kutikov A, Uzzo RG, Caraway A, Reese CT, Egleston BL, Chen DY, Viterbo R, Greenberg, RE, Wong YN, Raman JD, Boorjian SA. Use of systemic therapy and factors affecting survival for patients undergoing cytoreductive nephrectomy. BJU Int 2010;106(2):218-23. PMCID: PMC2906619
  • Dorgan JF, Spittle CS, Egleston BL, Shaw CM, Kahle LL, Brinton LA. Assay reproducibility and within-person variation of mullerian inhibiting substance. Fertil Steril 2010;94(1):301-4. PMCID: PMC2876207
  • Scott WJ, Matteotti RS, Egleston BL, Oseni S, Flaherty JF. A comparison of perioperative outcomes of Video-Assisted Thoracic Surgical (VATS) Lobectomy with open thoracotomy and lobectomy: Results of an analysis using propensity score based weighting. Ann Surg Innov Res 2010;4(1):1.
  • Lango MN, Egleston B, Ende K, Feigenberg S, D'Ambrosio DJ, Cohen RB, Ahmad S, Nicolaou N, Ridge JA. Impact of neck dissection on long-term feeding tube dependence in patients with head and neck cancer treated with primary radiation or chemoradiation. Head Neck 2010;32(3):341-347.
  • Kaplan DJ, Boorjian SA, Ruth K, Egleston BL, Chen DY, Viterbo R, Uzzo RG, Buyyounouski MK, Raysor S, Giri VN. Evaluation of the Prostate Cancer Prevention Trial Risk calculator in a high-risk screening population. BJU Int 2010;105(3):334-337.
  • Wang C, Miller SM, Egleston BL, Hay JL, Weinberg DS. Beliefs about the causes of breast and colorectal cancer among women in the general population. Cancer Causes Control 2010;21(1):99-107. PMCID: PMC2809801
  • Kutikov A, Egleston BL, Wong YN, Uzzom RG. Reply to J. Lagro et al and G. Lughezzani et al. J Clin Oncol 2010;28(18):e301.
  • Kutikov A, Egleston BL, Wong YN, Uzzo RG. Evaluating overall survival and competing risks of death in patients with localized renal cell carcinoma using a comprehensive nomogram. J Clin Oncol 2010;10;28(2):311-317. (with reply)
  • Dorgan JF, Stanczyk FZ, Egleston BL, Kahle LL, Shaw CM, Spittle CS, Godwin AK, Brinton LA. Prospective case-control study of serum mullerian inhibiting substance and breast cancer risk. J Natl Cancer Inst 2009;101(21):1501-1509.
  • Vig HS, Armstrong J, Egleston BL, Mazar C, Toscano M, Bradbury AR, Daly MB, Meropol NJ. Cancer genetic risk assessment and referral patterns in primary care. Genet Test Mol Biomarkers 2009;13(6):735-741.
  • Kurland BF, Johnson LL, Egleston BL, Diehr PH, Longitudinal Data with Follow-up Truncated by Death: Match the Analysis Method to Research Aims. Stat Sci 2009;24(2):211-222.
  • Wong YN, Freedland SJ, Egleston B, Vapiwala N, Uzzo R, Armstrong K. The role of primary androgen deprivation therapy in localized prostate cancer. European Urology 2009;56(4):609-616. PMCID: PMC2791191
  • Stitzenberg KB, Sigurdson ER, Egleston BL, Starkey RB, Meropol NJ. Centralization of cancer surgery: implications for patient access to optimal care. J Clin Oncol 2009;27(28):4671-4678.
  • Bleicher RJ, Ciocca RM, Egleston BL, Sesa L, Evers K, Sigurdson ER, Morrow M. Association of routine pretreatment magnetic resonance imaging with time to surgery, mastectomy rate, and margin status. J Am Coll Surg 2009;209(2):180-187.
  • Fang CY, Egleston BL, Brown KM, Lavigne JV, Stevens VJ, Barton BA, Chandler DW, Dorgan JF. Family cohesion moderates the relation between free testosterone and delinquent behaviors in adolescent boys and girls. J. Adolesc Health 2009;44(6):590-597.
  • Coups EJ, Ostroff JS, Feinstein MB, Steingart RM, Egleston BL, Wilson DJ, Park BJ. Correlates of physical activity among lung cancer survivors. Psycho-Oncol 2009;18(4):395-404.
  • Burtness B, Gibson M, Egleston BL, Mehra R, Thomas L, Sipples R, McGurk M, Lacy J, Watkins S, Murren JR, Forastiere AA. Phase II trial of docetaxel/irinotecan combination in advanced esophageal cancer. Annals of Oncology 2009;20(7):1242-1248. PMCID: PMC2699385
  • Coups EJ, Park BJ, Feinstein MB, Steingard RM, Egleston BL, Wilson DS, Ostroff JS. Physical activity among lung cancer survivors: changes across the cancer trajectory and associations with quality of life. Cancer Epidemiol. Biomarkers Prev 2009;18(2):664-672.
  • Giri V, Egleston BL, Ruth K, Uzzo RG, Chen DYT, Buyyounouski M, Raysor S, Hooker S. Race, genetic West African ancestry, and prostate cancer prediction by PSA in prospectively screened high-risk men. Cancer Prev Res 2009;2(3):244-250.
  • Scoll BJ, Wong YN, Egleston BL, Kunkle DA, Saad IR, Uzzo RG. Age, tumor size and relative survival of localized renal cell carcinoma: A survelliance, epidemiology and end results analysis. J. Urol. 2009;181(2):506-511. PMCID: PMC2703466
  • Wong YN, Freedland S, Egleston BL, Hudes G. Role of androgen deprivation therapy in node positive prostate cancer. J Cli. Oncol 2009;27:100-105,.
  • Rothman J, Egleston B, Wong YN, Iffrig K, Lebovitch S, Uzzo RG. Histopathologic Characteristics of Localized Renal Cell Carcinoma Correlate with Tumor Size: A SEER Analysis. J Urol 2009;181:29-33; discussion 33-34. PMCID: PMC2782573
  • Meropol NJ, Egleston BL, Buzaglo JS, Benson AB, Cegala DJ, Diefenbach MA, Fleisher L, Miller SM. Cancer patient preferences for quality of life. Cancer 2008;113:3459-3466.
  • Heckman CJ, Egleston BL, Wilson DB, Ingersoll KS. A Preliminary Investigation of the Predictors of Tanning Dependence. Am. J. Health Behav 2008;32(5):451-464.
  • Psyrri A, Egleston B, Weinberger P, Yu Z, Kowalski D, Sasaki C, Haffty B, Rimm D, Burtness B. Correlates and determinants of nuclear epidermal growth factor receptor content in an oropharyngeal cancer tissue microarray. Cancer Epidemiol Biomarkers Prev 2008;6:1486-1492.
  • Fleisher L, Buzaglo J, Collins M, Millard J, Miller SM, Egleston BL, Solarino N, Trinastic J, Cegala DJ, Benson AB 3rd, Schulman KA, Weinfurt KP, Sulmasy D, Diefenbach MA, Meropol NJ. Using health communication best practices to develop a web-based provider-patient communication aid: the CONNECT study. Patient Educ Couns 2008;71(3):378-387.
  • Barsevick AM, Montgomery SV, Ruth K, Ross EA, Egleston BL, Bingler R, Malick J, Miller SM, Cescon TP, Daly MB. Intention to communicate BRCA1/BRCA2 genetic test results to the family. J Fam Psychol 2008;22(2):303-312.
  • Kunkle DA, Egleston BL, Uzzo RG. Excise, ablate, or observe: the small renal mass dilemma - a meta-analysis and review. J Urol 2008;179(4):1227-33; discussion 1233-1234.
  • Singh MK, Dadke D, Nicolas E, Serebriiskii IG, Apostolou S, Canutescu A, Egleston BL, Golemis EA. A Novel Cas Family Member, HEPL, Regulates FAK and Cell Spreading. Mol Biol Cell 2008;19(4):1627-1636.
  • Mackenzie EJ, Rivara FP, Jurkovich GJ, Nathens AB, Egleston BL, Salkever DS, Frey KP, Scharfstein DO. The impact of trauma-center care on functional outcomes following major lower-limb trauma. J Bone Joint Surg Am 2008;90(1):101-109.
  • Mackenzie EJ, Rivara FP, Jurkovich GJ, Nathens AB, Frey KP, Egleston BL, Salkever DS, Weir S, Scharfstein DO. The National Study on Costs and Outcomes of Trauma. J Trauma 2007;63(6 Suppl):S54-67; discussion S81-86.
  • Narra K, Mullins SR, Lee HO, Strzemkowski-Brun B, Magalong K, Christiansen VJ, McKee PA, Egleston B, Cohen SJ, Weiner LM, Meropol NJ, Cheng JD. Phase II trial of single agent val-boropro inhibiting fibroblast activation protein in patients with metastatic colorectal cancer. Cancer Biol Ther 2007;6(11):1691-1699.
  • Yu A, Weinberger PM, Sasaki C, Egleston BL, Speier WF, Haffty B, Kowalski D, Camp R, Rimm D, Vairaktaris E, Burtness B, Psyrri A. Phosphorylation of akt (Ser473) predicts poor clinical outcome in oropharyngeal squamous cell cancer. Cancer Epidemiol Biomarkers Prev 2007;16(3):553-558.
  • Nathens AB, Rivara FP, Mackenzie EJ, Maier RV, Wang J, Egleston B, Scharfstein DO, Jurkovich GJ. The Impact of an Intensivist-Model ICU on Trauma-Related Mortality. Ann Surg 2006;244(4):545-554.
  • MacKenzie EJ, Rivara FP, Jurkovich GJ, Nathens AB, Frey KP, Egleston BL, Salkever DS, Scharfstein DO. Measuring the effectiveness of trauma center care on mortality. N Engl J Med 2006;354:366-378.
  • Freeman EE, Egleston BL, West SK, Bandeen-Roche K, Rubin G. Visual acuity change and mortality in older adults. Invest Ophthalmol Vis Sci 2005;46:4040-4045.
  • Merenstein D, Egleston BL, Diener-West M. Lengths of stay and costs associated with children's hospitals. Pediatrics 2005;115:839-844.
  • Meltzer D, Egleston B, Abdalla I. Patterns of prostate cancer treatment by clinical stage and age. Am J Public Health 2001;91:126-128.
  • Rudberg MA, Egleston BL, Grant MD, Brody JA. Effectiveness of feeding tubes in nursing home residents with swallowing disorders. JPEN J Parenter Enteral Nutr 2000;24:97-102.
  • Meltzer D, Egleston B, Stoffel D, Dasbach E. Effect of future costs on cost-effectiveness of medical interventions among young adults: the example of intensive therapy for type 1 diabetes mellitus. Med Care 2000;38:679-85.
  • Meltzer D, Egleston B. How patients with diabetes perceive their risk for major complications. Eff Clin Pract 2000;3:7-15.
  • Suri DN, Egleston BL, Brody JA, Rudberg MA. Nursing home resident use of care directives. J Gerontol A Biol Sci Med Sci 1999;54:M225-M229.
  • Heymann SJ, Earle A, Egleston B. Parental availability for the care of sick children. Pediatrics 1996;98:226-230.